Analysts see promise in FibroGen's early Duchenne study — now they want to see a pivotal trial
Apart from Pfizer $PFE, FibroGen $FGEN on Friday also presented early data on its drug for Duchenne muscular dystrophy.
The drug, pamrevlumab, is a monoclonal antibody to connective tissue growth factor (CTGF) currently under development as a treatment for non-ambulatory DMD patients, idiopathic pulmonary fibrosis and locally advanced pancreatic cancer. On Friday, the San Francisco-based drug developer unveiled early data from a small, single arm study at the Parent Project Muscular Dystrophy conference in Orlando, Florida.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.